A brief review on the mode of action of antinematodal drugs

1. Holden-Dye L, & Walker RJ: Avermectin and avermectin derivatives are antagonists at the 4-aminobutyric acid (GABA) receptor on the somatic muscle cells of Ascaris; is this the site of anthelmintic action? Parasitology 1990, 101 Pt 2: 265-271.10.1017/S0031182000063320Search in Google Scholar

2. Hotez PJ, Brindley PJ, Bethony JM, King CH, Pearce EJ, Jacobson J: Helminth infections: the great neglected tropical diseases. J Clin Invest 2008, 118(4):1311-1321.10.1172/JCI34261Search in Google Scholar

3. Martin RJ, Robertson AP, Bjorn H: Target sites of anthelmintics. Parasitology 1997, 114 Suppl: S111-124.10.1017/S0031182097001029Search in Google Scholar

4. Pink R, Hudson A, Mouries MA, Bendig M: Opportunities and challenges in antiparasitic drug discovery. Nat Rev Drug Discov 2005, 4: 727-740.10.1038/nrd1824Search in Google Scholar

5. DiMasi JA, Hansen RW, Grabowski HG: The price of innovation: new estimates of drug development costs. J Health Econ 2003, 22: 151-185.10.1016/S0167-6296(02)00126-1Search in Google Scholar

6. Evans T, Chapple N: The animal health market. Nat Rev Drug Discov 2002, 1: 937-938.10.1038/nrd97512474851Search in Google Scholar

7. Martin RJ, Robertson AP: Control of nematode parasites with agents acting on neuromusculature systems: lessons for neuropeptide ligand discovery. Adv Exp Med Biol 2010, 692: 138-154.10.1007/978-1-4419-6902-6_7373210321189677Search in Google Scholar

8. Morgan S, Grootendorst P, Lexchin J, Cunningham C, Greyson D: The cost of drug development: a systematic review. Health Policy 2011, 100: 4-17.10.1016/j.healthpol.2010.12.00221256615Search in Google Scholar

9. Crump A, Omura S: Ivermectin, ‘wonder drug’ from Japan: the human use perspective. Proc Jpn Acad Ser B Phys Biol Sci 2011, 87: 13-28.10.2183/pjab.87.13304374021321478Search in Google Scholar

10. Geary TG: Ivermectin 20 years on: maturation of a wonder drug. Trends Parasitol 2005, 21: 530-532.10.1016/j.pt.2005.08.01416126457Search in Google Scholar

11. Omura S: Ivermectin: 25 years and still going strong. Int J Antimicrob Agents 2008, 31: 91-98.10.1016/j.ijantimicag.2007.08.023Search in Google Scholar

12. McKellar QA, Scott EW: The benzimidazole anthelmintic agents--a review. J Vet Pharmacol Ther 1990, 13: 223-247.10.1111/j.1365-2885.1990.tb00773.xSearch in Google Scholar

13. Prichard RK: Mode of action of the anthelminthic thiabendazole in Haemonchus contortus. Nature 1970, 228: 684-685.10.1038/228684a0Search in Google Scholar

14. Tejada P, Sanchez-Moreno M, Monteoliva M, Gomez-Banqueri H: Inhibition of malate dehydrogenase enzymes by benzimidazole anthelmintics. Vet Parasitol 1987, 24: 269-274.10.1016/0304-4017(87)90048-3Search in Google Scholar

15. Lacey E: Mode of action of benzimidazoles. Parasitol Today 1990, 6: 112-115.10.1016/0169-4758(90)90227-USearch in Google Scholar

16. Aceves J, Erlij D, Martinez-Maranon R: The mechanism of the paralysing action of tetramisole on Ascaris somatic muscle. Br J Pharmacol 1970, 38: 602-607.10.1111/j.1476-5381.1970.tb10601.xSearch in Google Scholar

17. Raeymaekers AH, Allewijn FT, Vandenberk J, Demoen PJ, Van Offenwert TT, Janssen PA: Novel broad-spectrum anthelmintics. Tetramisole and related derivatives of 6-arylimidazo[2,1-b]thiazole. J Med Chem 1966, 9: 545-551.10.1021/jm00322a023Search in Google Scholar

18. Raeymaekers AH, Roevens LF, Janssen PA: The absolute configurations of the optical isomers of the broad spectrum anthelmintic tetramisole. Tetrahedron Lett 1967, 16: 1467-1470.10.1016/S0040-4039(00)90983-3Search in Google Scholar

19. Thienpont D, Vanparijs OF, Raeymaekers AH, Vandenberk J, Demoen JA, Allewijn FT, Marsboom RP, Niemegeers CJ, Schellekens KH, Janssen PA: Tetramisole (R 8299), a new, potent broad spectrum anthelmintic. Nature 1966, 209: 1084-1086.10.1038/2091084a05925183Search in Google Scholar

20. Thienpont D, Brugmans J, Abadi K, Tanamal S: Tetramisole in the treatment of nematode infections in man. Am J Trop Med Hyg 1969, 18: 520-525.10.4269/ajtmh.1969.18.5204894001Search in Google Scholar

21. Van den Bossche H, Janssen PA: The biochemical mechanism of action of the anthelmintic drug tetramisole. Life Sci 1967, 6: 1781-1792.10.1016/0024-3205(67)90150-6Search in Google Scholar

22. Qian H, Martin RJ, Robertson AP: Pharmacology of N-, L-, and B-subtypes of nematode nAChR resolved at the single-channel level in Ascaris suum. FASEB J 2006, 20: 2606-2608.10.1096/fj.06-6264fjeSearch in Google Scholar

23. Robertson AP, Bjorn HE, Martin RJ: Resistance to levamisole resolved at the single-channel level. FASEB J 1999, 13: 749-760.10.1096/fasebj.13.6.749Search in Google Scholar

24. Robertson SJ, Martin RJ: Levamisole-activated single-channel currents from muscle of the nematode parasite Ascaris suum. Br J Pharmacol 1993, 108: 170-178.10.1111/j.1476-5381.1993.tb13458.xSearch in Google Scholar

25. Buxton SK, Charvet CL, Neveu C, Cabaret J, Cortet J, Peineau N, Abongwa M, Courtot E, Robertson AP, Martin RJ: Investigation of acetylcholine receptor diversity in a nematode parasite leads to characterization of tribendimidine- and derquantel-sensitive nAChRs. PLoS Pathog 2014, 10: e1003870.10.1371/journal.ppat.1003870Search in Google Scholar

26. Trent C, Tsuing N, Horvitz HR: Egg-laying defective mutants of the nematode Caenorhabditis elegans. Genetics 1983, 104: 619-647.10.1093/genetics/104.4.619Search in Google Scholar

27. Aubry ML, Cowell P, Davey MJ, Shevde S. Aspects of the pharmacology of a new anthelmintic: pyrantel. Br J Pharmacol 1970, 38: 332-344.10.1111/j.1476-5381.1970.tb08521.xSearch in Google Scholar

28. Martin RJ: Modes of action of anthelmintic drugs. Vet J 1997, 154: 11-34.10.1016/S1090-0233(05)80005-XSearch in Google Scholar

29. Austin WC, Courtney W, Danilewicz JC, Morgan DH, Conover LH, Howes HL, Jr., Lynch JE, McFarland JW, Cornwell RL, Theodorides VJ: Pyrantel tartrate, a new anthelmintic effective against infections of domestic animals. Nature 1966, 212: 1273-1274.10.1038/2121273b021105312Search in Google Scholar

30. Howes HL, Jr., Lynch JE: Anthelmintic studies with pyrantel. I. Therapeutic and prophylactic efficacy against the enteral stages of various helminths in mice and dogs. J Parasitol 1967, 53: 1085-1091.10.2307/3276845Search in Google Scholar

31. McFarland JW, Howes HL, Jr.: Novel anthelmintic agents. 6. Pyrantel analogs with activity against whipworm. J Med Chem 1972, 15: 365-368.10.1021/jm00274a008Search in Google Scholar

32. Martin RJ, Verma S, Levandoski M, Clark CL, Qian H, Stewart M., Robertson AP: Drug resistance and neurotransmitter receptors of nematodes: recent studies on the mode of action of levamisole. Parasitology 2005, 131 Suppl: S71-84.10.1017/S0031182005008668Search in Google Scholar

33. Robertson SJ, Pennington AJ, Evans AM, Martin RJ: The action of pyrantel as an agonist and an open channel blocker at acetylcholine receptors in isolated Ascaris suum muscle vesicles. Eur J Pharmacol 1994, 271: 273-282.10.1016/0014-2999(94)90784-6Search in Google Scholar

34. Martin RJ, Clark CL, Trailovic SM, Robertson AP: Oxantel is an N-type (methyridine and nicotine) agonist not an L-type (levamisole and pyrantel) agonist: classification of cholinergic anthelmintics in Ascaris. Int J Parasitol 2004, 34: 1083-1090.10.1016/j.ijpara.2004.04.01415313135Search in Google Scholar

35. Dale VM, Martin RJ: Oxantel-activated single channel currents in the muscle membrane of Ascaris suum. Parasitology 1995, 110 (Pt 4): 437-448.10.1017/S0031182000064775Search in Google Scholar

36. Bamgbose SO, Marquis VO, Salako LA: Some pharmacological effects of the nematocide, morantel. Br J Pharmacol 1973, 47: 117-123.10.1111/j.1476-5381.1973.tb08164.x17765194352084Search in Google Scholar

37. Cornwell RL, Blore MA: Anthelmintic activity of pyrantel and morantel against adult and larval stages of Nippostrongylus brasiliensis and Nematospiroides dubius. Ann Trop Med Parasitol 1970, 64: 525-531.10.1080/00034983.1970.116867235498790Search in Google Scholar

38. Evans AM, Martin RJ: Activation and cooperative multi-ion block of single nicotinic-acetylcholine channel currents of Ascaris muscle by the tetrahydropyrimidine anthelmintic, morantel. Br J Pharmacol 1996, 118: 1127-1140.10.1111/j.1476-5381.1996.tb15515.x19095928818335Search in Google Scholar

39. Courtot E, Charvet CL, Beech RN, Harmache A, Wolstenholme AJ, Holden-Dye L, O’Connor V, Peineau N, Woods DJ, Neveu C: Functional characterization of a novel class of morantel-sensitive acetylcholine receptors in nematodes. PLoS Pathog 2015, 11: e1005267.10.1371/journal.ppat.1005267466664526625142Search in Google Scholar

40. Abongwa M, Baber KE, Martin RJ, Robertson AP: The cholinomimetic morantel as an open channel blocker of the Ascaris suum ACR-16 nAChR. Invert Neurosci 2016, 16: 10.10.1007/s10158-016-0193-427995347Search in Google Scholar

41. Burg RW, Miller BM, Baker EE, Birnbaum J, Currie SA, Hartman R, Kong YL, Monaghan RL, Olson G, Putter I, Tunac JB, Wallick H, Stapley EO, Oiwa R, Omura S: Avermectins, new family of potent anthelmintic agents: producing organism and fermentation. Antimicrob Agents Chemother 1979, 15: 361-367.10.1128/AAC.15.3.361352666464561Search in Google Scholar

42. Takiguchi Y, Mishima H, Okuda M, Terao M, Aoki A, Fukuda R: Milbemycins, a new family of macrolide antibiotics: fermentation, isolation and physico-chemical properties. J Antibiot (Tokyo) 1980, 33: 1120-1127.10.7164/antibiotics.33.11207451362Search in Google Scholar

43. Takiguchi Y, Ono M, Muramatsu S, Ide J, Mishima H, Terao M: Milbemycins, a new family of macrolide antibiotics. Fermentation, isolation and physico-chemical properties of milbemycins D, E, F, G, and H. J Antibiot (Tokyo) 1983, 36: 502-508.10.7164/antibiotics.36.5026874568Search in Google Scholar

44. Davies HG, Green RH: Avermectins and milbemycins. Nat Prod Rep 1986, 3: 87-121.10.1039/np98603000873526202Search in Google Scholar

45. McKellar QA, Benchaoui HA: Avermectins and milbemycins. J Vet Pharmacol Ther 1996, 19: 331-351.10.1111/j.1365-2885.1996.tb00062.x8905567Search in Google Scholar

46. Cully DF, Vassilatis DK, Liu KK, Paress PS, Van der Ploeg LH, Schaeffer JM, Arena JP: Cloning of an avermectin-sensitive glutamate-gated chloride channel from Caenorhabditis elegans. Nature 1994, 371: 707-711.10.1038/371707a07935817Search in Google Scholar

47. Wolstenholme AJ, Rogers AT: Glutamate-gated chloride channels and the mode of action of the avermectin/milbemycin anthelmintics. Parasitology 2005, 131 Suppl: S85-95.10.1017/S003118200500821816569295Search in Google Scholar

48. Abongwa M, Buxton SK, Robertson AP, Martin RJ: Curiouser and curiouser: the macrocyclic lactone, abamectin, is also a potent inhibitor of pyrantel/tribendimidine nicotinic acetylcholine receptors of gastro-intestinal worms. PLoS One 2016, 11: e0146854.10.1371/journal.pone.0146854470907326751958Search in Google Scholar

49. Holden-Dye L, Walker RJ: Avermectin and avermectin derivatives are antagonists at the 4-aminobutyric acid (GABA) receptor on the somatic muscle cells of Ascaris; is this the site of anthelmintic action? Parasitology. 1990, Oct;101 Pt 2:265-271.10.1017/S0031182000063320Search in Google Scholar

50. Puttachary S, Trailovic SM, Robertson AP, Thompson DP, Woods DJ, Martin RJ: Derquantel and abamectin: effects and interactions on isolated tissues of Ascaris suum. Mol Biochem Parasitol 2013, 188: 79-86.10.1016/j.molbiopara.2013.02.004386455523523993Search in Google Scholar

51. Ottesen EA, Campbell WC: Ivermectin in human medicine. J Antimicrob Chemother 1994, 34: 195-203.10.1093/jac/34.2.1957814280Search in Google Scholar

52. Shan Q, Haddrill JL, Lynch JW: Ivermectin, an unconventional agonist of the glycine receptor chloride channel. J Biol Chem 2001, 276: 12556-12564.10.1074/jbc.M01126420011278873Search in Google Scholar

53. Krause RM, Buisson B, Bertrand S, Corringer PJ, Galzi JL, Changeux JP, Bertrand D: Ivermectin: a positive allosteric effector of the alpha7 neuronal nicotinic acetylcholine receptor. Mol Pharmacol 1998, 53: 283-294.10.1124/mol.53.2.2839463487Search in Google Scholar

54. Ducray P, Gauvry N, Pautrat F, Goebel T, Fruechtel J, Desaules Y, Weber SS, Bouvier J, Wagner T, Froelich O, Kaminsky R: Discovery of amino-acetonitrile derivatives, a new class of synthetic anthelmintic compounds. Bioorg Med Chem Lett 2008, 18: 2935-2938.10.1016/j.bmcl.2008.03.07118400497Search in Google Scholar

55. Kaminsky R, Ducray P, Jung M, Clover R, Rufener L, Bouvier J, Weber SS, Wenger A, Wieland-Berghausen S, Goebel T, Gauvry N, Pautrat F, Skripsky T, Froelich O, Komoin-Oka C, Westlund B, Sluder A, Mäser P: A new class of anthelmintics effective against drugresistant nematodes. Nature 2008a, 452: 176-180.10.1038/nature0672218337814Search in Google Scholar

56. Kaminsky R, Gauvry N, Schorderet Weber S, Skripsky T, Bouvier J, Wenger A, Schroeder F, Desaules Y, Hotz R, Goebel T, Hosking BC, Pautrat F, Wieland-Berghausen S, Ducray P: Identification of the amino-acetonitrile derivative monepantel (AAD 1566) as a new anthelmintic drug development candidate. Parasitol Res 2008b, 103: 931-939.10.1007/s00436-008-1080-7249143818594861Search in Google Scholar

57. Baur R, Beech R, Sigel E, Rufener L: Monepantel irreversibly binds to and opens Haemonchus contortus MPTL-1 and Caenorhabditis elegans ACR-20 receptors. Mol Pharmacol 2015, 87: 96-102.10.1124/mol.114.09565325352042Search in Google Scholar

58. Lecova L, Stuchlikova L, Prchal L, Skalova L: Monepantel: the most studied new anthelmintic drug of recent years. Parasitology 2014, 141: 1686-1698.10.1017/S003118201400140125200288Search in Google Scholar

59. Rufener L, Bedoni N, Baur R, Rey S, Glauser DA, Bouvier J, Beech R, Sigel E, Puoti A: acr-23 Encodes a monepantel-sensitive channel in Caenorhabditis elegans. PLoS Pathog 2013, 9: e1003524.10.1371/journal.ppat.1003524373847723950710Search in Google Scholar

60. Rufener L, Maser P, Roditi I, Kaminsky R. Haemonchus contortus acetylcholine receptors of the DEG-3 subfamily and their role in sensitivity to monepantel. PLoS Pathog 2009, 5: e1000380.10.1371/journal.ppat.1000380266288619360096Search in Google Scholar

61. Lee BH, Clothier MF, Dutton FE, Nelson SJ, Johnson SS, Thompson DP, Geary TG, Whaley HD, Haber CL, Marshall VP, Kornis GI, McNally PL, Ciadella JI, Martin DG, Bowman JW, Baker CA, Coscarelli EM, Alexander-Bowman SJ, Davis JP, Zinser EW, Wiley V, Lipton MF, Mauragis MAMarcfortine and paraherquamide class of anthelmintics: discovery of PNU-141962. Curr Top Med Chem 2002, 2: 779-793.10.2174/1568026023393705Search in Google Scholar

62. Little PR, Hodge A, Maeder SJ, Wirtherle NC, Nicholas DR, Cox GG, Conder GA: Efficacy of a combined oral formulation of derquantel-abamectin against the adult and larval stages of nematodes in sheep, including anthelmintic-resistant strains. Vet Parasitol 2011, 181: 180-193.10.1016/j.vetpar.2011.05.008Search in Google Scholar

63. Rufener L, Baur R, Kaminsky R, Maser P, Sigel E: Monepantel allosterically activates DEG-3/DES-2 channels of the gastrointestinal nematode Haemonchus contortus. Mol Pharmacol 2010, 78: 895-902.10.1124/mol.110.066498Search in Google Scholar

64. Robertson AP, Clark CL, Burns TA, Thompson DP, Geary TG, Trailovic SM, Martin RJ: Paraherquamide and 2-deoxy-paraherquamide distinguish cholinergic receptor subtypes in Ascaris muscle. J Pharmacol Exp Ther 2002, 302: 853-860.10.1124/jpet.102.034272Search in Google Scholar

65. Geurden T, Hodge A, Noe L, Winstanley D, Bartley DJ, Taylor M, Morgan C, Fraser SJ, Maeder S, Bartram D: The efficacy of a combined oral formulation of derquantel-abamectin against anthelmintic resistant gastro-intestinal nematodes of sheep in the UK. Vet Parasitol 2012, 189: 308-316.10.1016/j.vetpar.2012.04.008Search in Google Scholar

66. Anderson N, Martin PJ, Jarrett RG: Mixtures of anthelmintics: a strategy against resistance. Aust Vet J 1988, 65: 62-64.10.1111/j.1751-0813.1988.tb07355.xSearch in Google Scholar

67. Bartram DJ, Leathwick DM, Taylor MA, Geurden T, Maeder SJ: The role of combination anthelmintic formulations in the sustainable control of sheep nematodes. Vet Parasitol 2012, 186: 151-158.10.1016/j.vetpar.2011.11.030Search in Google Scholar

68. Sasaki T, Takagi M, Yaguchi T, Miyadoh S, Okada T, Koyama M: A new anthelmintic cyclodepsipeptide, PF1022A. J Antibiot (Tokyo) 1992, 45: 692-697.10.7164/antibiotics.45.692Search in Google Scholar

69. Harder A, Schmitt-Wrede HP, Krucken J, Marinovski P, Wunderlich F, Willson J, Amliwala K, Holden-Dye L, Walker R: Cyclooctadepsipeptides--an anthelmintically active class of compounds exhibiting a novel mode of action. Int J Antimicrob Agents 2003, 22: 318-331.10.1016/S0924-8579(03)00219-XSearch in Google Scholar

70. Harder A, Holden-Dye L, Walker R, Wunderlich F: Mechanisms of action of emodepside. Parasitol Res 2005, 97 Suppl 1: S1-10.10.1007/s00436-005-1438-z16228263Search in Google Scholar

71. Harder A, von Samson-Himmelstjerna G: Activity of the cyclic depsipeptide emodepside (BAY 44-4400) against larval and adult stages of nematodes in rodents and the influence on worm survival. Parasitol Res 2001, 87: 924-928.10.1007/s004360100479Search in Google Scholar

72. Kulke D, Krucken J, Demeler J, Harder A, Mehlhorn H, von Samson-Himmelstjerna G: In vitro efficacy of cyclooctadepsipepdtides and aminophenylamidines alone and in combination against third-stage larvae and adult worms of Nippostrongylus brasiliensis and first-stage larvae of Trichinella spiralis. Parasitol Res 2013, 112: 335-345.10.1007/s00436-012-3141-1Search in Google Scholar

73. Kulke D, Krucken J, Harder A, Krebber R, Fraatz K, Mehlhorn H, von Samson-Himmelstjerna G: In vivo efficacy of PF1022A and nicotinic acetylcholine receptor agonists alone and in combination against Nippostrongylus brasiliensis. Parasitology 2013, 140: 1252-1265.10.1017/S0031182013000632Search in Google Scholar

74. Kulke D, Krucken J, Harder A, von Samson-Himmelstjerna G: Efficacy of cyclooctadepsipeptides and aminophenylamidines against larval, immature and mature adult stages of a parasitologically characterized trichurosis model in mice. PLoS Negl Trop Dis 2014, 8: e2698.10.1371/journal.pntd.0002698Search in Google Scholar

75. Zahner H, Taubert A, Harder A, von Samson-Himmelstjerna G. Effects of Bay 44-4400, a new cyclodepsipeptide, on developing stages of filariae (Acanthocheilonema viteae, Brugia malayi, Litomosoides sigmodontis) in the rodent Mastomys coucha. Acta Trop 2001, 80: 19-28.10.1016/S0001-706X(01)00144-9Search in Google Scholar

76. Zahner H, Taubert A, Harder A, von Samson-Himmelstjerna G: Filaricidal efficacy of anthelmintically active cyclodepsipeptides. Int J Parasitol 2001b, 31: 1515-1522.10.1016/S0020-7519(01)00263-6Search in Google Scholar

77. von Samson-Himmelstjerna G, Harder A, Sangster NC, Coles GC: Efficacy of two cyclooctadepsipeptides, PF1022A and emodepside, against anthelmintic-resistant nematodes in sheep and cattle. Parasitology 2005, 130: 343-347.10.1017/S0031182004006523Search in Google Scholar

78. Holden-Dye L, O’Connor V, Hopper NA, Walker RJ, Harder A, Bull K, Guest M: SLO, SLO, quick, quick, slow: calcium-activated potassium channels as regulators of Caenorhabditis elegans behaviour and targets for anthelmintics. Invert Neurosci 2007, 7: 199-208.10.1007/s10158-007-0057-z17962986Search in Google Scholar

79. Krucken J, Harder A, Jeschke P, Holden-Dye L, O’Connor V, Welz C, von Samson-Himmelstjerna G: Anthelmintic cyclcooctadepsipeptides: complex in structure and mode of action. Trends Parasitol 2012, 28: 385-394.10.1016/j.pt.2012.06.00522858281Search in Google Scholar

80. Martin RJ, Buxton SK, Neveu C, Charvet CL, Robertson AP: Emodepside and SL0-1 potassium channels: a review. Exp Parasitol 2012 132: 40-46.10.1016/j.exppara.2011.08.012326293621910990Search in Google Scholar

81. Guest M, Bull K, Walker RJ, Amliwala K, O’Connor V, Harder A, Holden-Dye L, Hopper NA: The calcium-activated potassium channel, SLO-1, is required for the action of the novel cyclo-octadepsipeptide anthelmintic, emodepside, in Caenorhabditis elegans. Int J Parasitol 2007, 37: 1577-1588.10.1016/j.ijpara.2007.05.006Search in Google Scholar

82. Willson J, Amliwala K, Davis A, Cook A, Cuttle MF, Kriek N, Hopper NA, O’Connor V, Harder A, Walker RJ, Holden-Dye L: Latrotoxin receptor signaling engages the UNC-13-dependent vesicle-priming pathway in C. elegans. Curr Biol 2004, 14: 1374-1379.10.1016/j.cub.2004.07.056Search in Google Scholar

83. Crisford A, Ebbinghaus-Kintscher U, Schoenhense E, Harder A, Raming K, O’Kelly I, Ndukwe K, O’Connor V, Walker RJ, Holden-Dye L: The cyclooctadepsipeptide anthelmintic emodepside differentially modulates nematode, insect and human calciumactivated potassium (SLO) channel alpha subunits. PLoS Negl Trop Dis 2015, 9: e0004062.10.1371/journal.pntd.0004062Search in Google Scholar

84. Kulke D, Krucken J, Welz C, von Samson-Himmelstjerna G, Harder A: In vivo efficacy of the anthelmintic tribendimidine against the cestode Hymenolepis microstoma in a controlled laboratory trial. Acta Trop 2012, 123: 78-84.10.1016/j.actatropica.2012.03.008Search in Google Scholar

85. Ren HN, Cheng BZ, Zhuang ZN: Experimental therapeutic efficacy of a new antihookworm drug, tribendimidin. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 1987, 5: 262-264.Search in Google Scholar

86. Xiao SH, Hui-Ming W, Tanner M, Utzinger J, Chong W. Tribendimidine: a promising, safe and broad-spectrum anthelmintic agent from China. Acta Trop 2005, 94: 1-14.10.1016/j.actatropica.2005.01.013Search in Google Scholar

87. Bergquist R: Tribendimidine: great expectations. Lancet Infect Dis 2016, 16: 1089-1091.10.1016/S1473-3099(16)30231-6Search in Google Scholar

88. Keiser J, Shu-Hua X, Chollet J, Tanner M, Utzinger J: Evaluation of the in vivo activity of tribendimidine against Schistosoma mansoni, Fasciola hepatica, Clonorchis sinensis, and Opisthorchis viverrini. Antimicrob Agents Chemother 2007, 51: 1096-1098.10.1128/AAC.01366-06180315717194822Search in Google Scholar

89. Steinmann P, Zhou XN, Du ZW, Jiang JY, Xiao SH, Wu ZX, Zhou H, Utzinger J: Tribendimidine and albendazole for treating soil-transmitted helminths, Strongyloides stercoralis and Taenia spp.: open-label randomized trial. PLoS Negl Trop Dis 2008, 2: e322.10.1371/journal.pntd.0000322256100518923706Search in Google Scholar

90. Wu ZX, Fang YY, Liu YS: Effect of a novel drug-enteric coated tribendimidine in the treatment of intestinal nematode infections. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 2006, 24: 23-26.Search in Google Scholar

91. Xiao SH, Xue J, Xu LL, Zheng Q, Qiang HQ, Zhang YN: The in vitro and in vivo effect of tribendimidine and its metabolites against Clonorchis sinensis. Parasitol Res 2009, 105: 1497-1507.10.1007/s00436-009-1579-619655171Search in Google Scholar

92. Xu LL, Jiang B, Duan JH, Zhuang SF, Liu YC, Zhu SQ, ZhangLP, Zhang HB, Xiao SH, Zhou XN: Efficacy and safety of praziquantel, tribendimidine and mebendazole in patients with co-infection of Clonorchis sinensis and other helminths. PLoS Negl Trop Dis 2014, 8: e3046.10.1371/journal.pntd.0003046413322825122121Search in Google Scholar

93. Xiao SH, Utzinger J, Tanner M, Keiser J, Xue J: Advances with the Chinese anthelminthic drug tribendimidine in clinical trials and laboratory investigations. Acta Trop 2013, 126: 115-126.10.1016/j.actatropica.2013.01.009Search in Google Scholar

94. Hu Y, Xiao SH, Aroian RV: The new anthelmintic tribendimidine is an L-type (levamisole and pyrantel) nicotinic acetylcholine receptor agonist. PLoS Negl Trop Dis 2009, 3: e499.10.1371/journal.pntd.0000499Search in Google Scholar

95. Robertson AP, Puttachary S, Buxton SK, Martin RJ: Tribendimidine: mode of action and nAChR subtype selectivity in Ascaris and Oesophagostomum. PLoS Negl Trop Dis 2015, 9: e0003495.10.1371/journal.pntd.0003495Search in Google Scholar

96. Coles GC, Jackson F, Pomroy WE, Prichard RK, von Samson-Himmelstjerna G, Silvestre A, Taylor MA, Vercruysse J: The detection of anthelmintic resistance in nematodes of veterinary importance. Vet Parasitol 2006, 136(3-4):167-185.10.1016/j.vetpar.2005.11.019Search in Google Scholar

97. Geerts S, Gryseels B: Drug resistance in human helminths: current situation and lessons from livestock. Clin Microbiol Rev 2000, 13(2):207-222.10.1128/CMR.13.2.207Search in Google Scholar

98. Geerts S1, Gryseels B: Anthelmintic resistance in human helminths: a review. Trop Med Int Health 2001, 6(11):915-921.10.1046/j.1365-3156.2001.00774.xSearch in Google Scholar

99. Sangster NC: Anthelmintic resistance: past, present and future. Int J Parasitol 1999, 29(1):115-124.10.1016/S0020-7519(98)00188-XSearch in Google Scholar

100. Conway DP: Variance in the effectivenes of thiabedazole against Haemonchus contortus in sheep. Am J Vet Res 1964, 25:844-846.Search in Google Scholar

101. Kaplan RM: Drug resistance in nematodes of veterinary importance: a status report. Trends Parasitol 2004, 20(10):477-481.10.1016/j.pt.2004.08.001Search in Google Scholar

102. Kaplan RM, Vidyashankar AN: An inconvenient truth: global worming and anthelmintic resistance. Vet Parasitol 2012, 186(1-2):70-78.10.1016/j.vetpar.2011.11.048Search in Google Scholar

103. Waller PJ: Anthelmintic resistance. Vet Parasitol 1997, 72(3-4):391-405.10.1016/S0304-4017(97)00107-6Search in Google Scholar

104. Gilleard JS: Understanding anthelmintic resistance: the need for genomics and genetics. Int J Parasitol 2006, 36(12):1227-1239.10.1016/j.ijpara.2006.06.010Search in Google Scholar

105. Jabbar A, Iqbal Z, Kerboeuf D, Muhammad G, Khan MN, Afaq M: Anthelmintic resistance: the state of play revisited. Life Sci 2006, 25;79(26):2413-2431.10.1016/j.lfs.2006.08.010Search in Google Scholar

106. James CE, Hudson AL, Davey MW: Drug resistance mechanisms in helminths: is it survival of the fittest? Trends Parasitol 2009, 25(7):328-335.10.1016/j.pt.2009.04.004Search in Google Scholar

107. Sangster NC, Gill J: Pharmacology of anthelmintic resistance. Parasitol Today 1999, 15(4):141-146.10.1016/S0169-4758(99)01413-1Search in Google Scholar

108. Wolstenholme AJ, Fairweather I, Prichard R, von Samson-Himmelstjerna G, Sangster NC: Drug resistance in veterinary helminths. Trends Parasitol 2004, 20(10):469-476.10.1016/j.pt.2004.07.01015363440Search in Google Scholar

109. Coles GC: Anthelmintic resistance--looking to the future: a UK perspective. Res Vet Sci. 2005, 78(2):99-108.10.1016/j.rvsc.2004.09.00115563915Search in Google Scholar

110. Leathwick DM: Modelling the benefits of a new class of anthelmintic in combination. Vet Parasitol 2012, 186(1-2):93-100.10.1016/j.vetpar.2011.11.05022169403Search in Google Scholar

111. Shalaby HA: Anthelmintics resistance; how to overcome it? Iran J Parasitol 2013, 8(1):18-32.Search in Google Scholar